← Back to Search

MVT-5873 for Bile Duct Cancer

Phase 2
Waitlist Available
Led By Jonathan M Hernandez, M.D.
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Primary tumors of the pancreas
Primary tumors of the bile duct and ampulla
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Eligible Conditions
  • Bile Duct Cancer
  • Pancreatic Cancer
  • Colon Cancer
  • Liver Metastases

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Grade 3-5 Adverse Events Related and/or Not Related to Drug
Number of Participants With Disease Recurrence At 1 Year
Secondary outcome measures
Define Disease Free Survival (DFS) for Participants Treated With Preoperative MVT-5873
Other outcome measures
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Side effects data

From 2022 Phase 2 trial • 10 Patients • NCT03801915
100%
Pleural effusion
100%
Hepatobiliary disorders - Other, Bile duct perforation
100%
Aspartate aminotransferase increased
100%
Blood bilirubin increased
100%
Creatinine increased
100%
Somnolence
100%
Urine output decreased
100%
Vomiting
100%
Abdominal infection
100%
Abdominal pain
100%
Confusion
100%
Lymphocyte count decreased
100%
Hyperkalemia
100%
Hypotension
100%
Alkaline phosphatase increased
100%
Alanine aminotransferase increased
100%
Anemia
100%
Dyspnea
100%
Hypoalbuminemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort 2 - Pre-operative Recommended Dose (RD) of MVT-5873 (HuMab-5B1)
Cohort 1 - Pre-operative Escalation Doses of MVT-5873 (HuMab-5B1)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort 2 - Pre-operative Recommended Dose (RD) of MVT-5873 (HuMab-5B1)Experimental Treatment2 Interventions
Pre-operative RD of MVT-5873, pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
Group II: Cohort 1 - Pre-operative Escalation Doses of MVT-5873 (HuMab-5B1)Experimental Treatment2 Interventions
Pre-operative escalation doses of MVT-5873, pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MVT-5873
2019
Completed Phase 2
~10
pancreatectomy or hepatectomy
2019
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,609 Previous Clinical Trials
40,915,636 Total Patients Enrolled
Jonathan M Hernandez, M.D.Principal InvestigatorNational Cancer Institute (NCI)
3 Previous Clinical Trials
112 Total Patients Enrolled

Frequently Asked Questions

~2 spots leftby Mar 2025